O	0	11	Ultraviolet	Ultraviolet	NN	B-NP
O	12	13	B	B	NN	I-NP
O	14	25	irradiation	irradiation	NN	I-NP
O	26	34	promotes	promote	VBZ	B-VP
O	35	46	tumorigenic	tumorigenic	JJ	B-NP
O	47	50	and	and	CC	I-NP
O	51	61	metastatic	metastatic	JJ	I-NP
O	62	72	properties	property	NNS	I-NP
O	73	75	in	in	IN	B-PP
B-Cancer	76	83	primary	primary	JJ	B-NP
I-Cancer	84	93	cutaneous	cutaneous	JJ	I-NP
I-Cancer	94	102	melanoma	melanoma	NN	I-NP
O	103	106	via	via	IN	B-PP
O	107	116	induction	induction	NN	B-NP
O	117	119	of	of	IN	B-PP
O	120	131	interleukin	interleukin	NN	B-NP
O	132	133	8	8	CD	I-NP
O	133	134	.	.	.	O

O	136	138	UV	UV	NN	B-NP
O	139	148	radiation	radiation	NN	I-NP
O	149	152	has	have	VBZ	B-VP
O	153	157	been	be	VBN	I-VP
O	158	163	shown	show	VBN	I-VP
O	164	166	to	to	TO	I-VP
O	167	171	play	play	VB	I-VP
O	172	173	a	a	DT	B-NP
O	174	178	role	role	NN	I-NP
O	179	181	in	in	IN	B-PP
O	182	185	the	the	DT	B-NP
O	186	196	initiation	initiation	NN	I-NP
O	197	199	of	of	IN	B-PP
O	200	205	human	human	JJ	B-NP
B-Cancer	206	215	cutaneous	cutaneous	JJ	I-NP
I-Cancer	216	224	melanoma	melanoma	NN	I-NP
O	224	225	,	,	,	O
O	226	229	but	but	CC	O
O	230	233	its	its	PRP$	B-NP
O	234	238	role	role	NN	I-NP
O	239	241	in	in	IN	B-PP
O	242	245	the	the	DT	B-NP
O	246	257	development	development	NN	I-NP
O	258	260	of	of	IN	B-PP
B-Cancer	261	270	malignant	malignant	JJ	B-NP
I-Cancer	271	279	melanoma	melanoma	NN	I-NP
O	280	282	to	to	TO	B-PP
O	283	286	the	the	DT	B-NP
O	287	297	metastatic	metastatic	JJ	I-NP
O	298	303	state	state	NN	I-NP
O	304	306	is	be	VBZ	B-VP
O	307	310	not	not	RB	O
O	311	315	very	very	RB	B-ADJP
O	316	320	well	well	RB	I-ADJP
O	321	328	defined	define	VBN	I-ADJP
O	328	329	.	.	.	O

O	330	338	Although	Although	IN	B-SBAR
O	339	347	previous	previous	JJ	B-NP
O	348	355	studies	study	NNS	I-NP
O	356	360	have	have	VBP	B-VP
O	361	373	concentrated	concentrate	VBN	I-VP
O	374	376	on	on	IN	B-PP
O	377	380	the	the	DT	B-NP
O	381	387	effect	effect	NN	I-NP
O	388	390	of	of	IN	B-PP
O	391	393	UV	UV	NN	B-NP
O	393	394	-	-	HYPH	I-NP
O	394	395	B	B	NN	B-NP
O	396	398	on	on	IN	B-PP
O	399	402	the	the	DT	B-NP
O	403	407	host	host	NN	I-NP
O	408	414	immune	immune	JJ	I-NP
O	415	423	response	response	NN	I-NP
O	423	424	,	,	,	O
O	425	428	the	the	DT	B-NP
O	429	435	effect	effect	NN	I-NP
O	436	438	of	of	IN	B-PP
O	439	441	UV	UV	NN	B-NP
O	441	442	-	-	HYPH	I-NP
O	442	443	B	B	NN	B-NP
O	444	446	on	on	IN	B-PP
O	447	450	the	the	DT	B-NP
B-Cell	451	456	tumor	tumor	NN	I-NP
I-Cell	457	462	cells	cell	NNS	I-NP
O	463	466	was	be	VBD	B-VP
O	467	470	not	not	RB	I-VP
O	471	481	elucidated	elucidate	VBN	I-VP
O	481	482	.	.	.	O

O	483	487	Here	Here	RB	B-ADVP
O	488	490	we	we	PRP	B-NP
O	491	495	show	show	VBP	B-VP
O	496	500	that	that	IN	B-SBAR
O	501	503	UV	UV	NN	B-NP
O	503	504	-	-	HYPH	B-NP
O	504	505	B	B	NN	I-NP
O	506	509	can	can	MD	B-VP
O	510	516	induce	induce	VB	I-VP
O	517	528	interleukin	interleukin	NN	B-NP
O	529	530	8	8	CD	I-NP
O	531	532	(	(	(	O
O	532	534	IL	IL	NN	B-NP
O	534	535	-	-	HYPH	O
O	535	536	8	8	CD	O
O	536	537	)	)	)	O
O	538	542	mRNA	mRNA	NN	B-NP
O	543	546	and	and	CC	I-NP
O	547	554	protein	protein	NN	I-NP
O	555	564	secretion	secretion	NN	I-NP
O	565	567	in	in	IN	B-PP
O	568	573	human	human	JJ	B-NP
B-Cancer	574	583	cutaneous	cutaneous	JJ	I-NP
I-Cancer	584	592	melanoma	melanoma	NN	I-NP
O	593	597	with	with	IN	B-PP
O	598	608	negligible	negligible	JJ	B-NP
O	609	619	expression	expression	NN	I-NP
O	620	622	of	of	IN	B-PP
O	623	625	IL	IL	NN	B-NP
O	625	626	-	-	HYPH	B-NP
O	626	627	8	8	CD	I-NP
O	627	628	.	.	.	O

O	629	631	UV	UV	NN	B-NP
O	631	632	-	-	HYPH	B-NP
O	632	633	B	B	NN	I-NP
O	633	634	-	-	HYPH	O
O	634	641	induced	induce	VBN	B-NP
O	642	644	IL	IL	NN	I-NP
O	644	645	-	-	HYPH	O
O	645	646	8	8	CD	B-NP
O	647	650	was	be	VBD	B-VP
O	651	665	constitutively	constitutively	RB	I-VP
O	666	675	expressed	express	VBN	I-VP
O	676	678	60	60	CD	B-NP
O	679	683	days	day	NNS	I-NP
O	684	689	after	after	IN	B-PP
O	690	701	irradiation	irradiation	NN	B-NP
O	702	704	in	in	IN	B-PP
B-Cancer	705	711	tumors	tumor	NNS	B-NP
O	712	721	implanted	implant	VBN	B-VP
O	722	724	in	in	IN	B-PP
O	725	729	mice	mouse	NNS	B-NP
O	729	730	.	.	.	O

O	731	740	Induction	Induction	NN	B-NP
O	741	743	of	of	IN	B-PP
O	744	746	IL	IL	NN	B-NP
O	746	747	-	-	HYPH	B-NP
O	747	748	8	8	CD	I-NP
O	749	752	was	be	VBD	B-VP
O	753	755	UV	UV	NN	B-NP
O	755	756	-	-	HYPH	B-NP
O	756	757	B	B	NN	I-NP
O	758	762	dose	dose	NN	I-NP
O	763	772	dependent	dependent	JJ	B-ADJP
O	773	776	and	and	CC	O
O	777	784	blocked	block	VBN	B-VP
O	785	787	by	by	IN	B-PP
O	788	801	cyclohexamide	cyclohexamide	NN	B-NP
O	801	802	,	,	,	O
O	803	813	indicating	indicate	VBG	B-VP
O	814	818	that	that	IN	B-SBAR
O	819	821	de	de	FW	B-NP
O	822	826	novo	novo	FW	I-NP
O	827	834	protein	protein	NN	I-NP
O	835	844	synthesis	synthesis	NN	I-NP
O	845	847	is	be	VBZ	B-VP
O	848	856	required	require	VBN	I-VP
O	857	860	for	for	IN	B-PP
O	861	864	its	its	PRP$	B-NP
O	865	875	expression	expression	NN	I-NP
O	875	876	.	.	.	O

O	877	880	The	The	DT	B-NP
O	881	883	UV	UV	NN	I-NP
O	883	884	-	-	HYPH	B-NP
O	884	894	irradiated	irradiate	VBN	I-NP
B-Cell	895	900	cells	cell	NNS	I-NP
O	901	913	demonstrated	demonstrate	VBD	B-VP
O	914	922	enhanced	enhance	VBN	I-VP
O	923	937	tumorigenicity	tumorigenicity	NN	B-NP
O	938	941	and	and	CC	O
O	942	952	metastatic	metastatic	JJ	B-NP
O	953	962	potential	potential	NN	I-NP
O	963	965	in	in	IN	B-PP
O	966	970	nude	nude	JJ	B-NP
O	971	975	mice	mouse	NNS	I-NP
O	975	976	.	.	.	O

O	977	980	The	The	DT	B-NP
O	981	989	increase	increase	NN	I-NP
O	990	992	in	in	IN	B-PP
O	993	1007	tumorigenicity	tumorigenicity	NN	B-NP
O	1008	1011	and	and	CC	O
O	1012	1022	metastatic	metastatic	JJ	B-NP
O	1023	1030	ability	ability	NN	I-NP
O	1031	1036	could	could	MD	B-VP
O	1037	1039	be	be	VB	I-VP
O	1040	1049	explained	explain	VBN	I-VP
O	1050	1052	by	by	IN	B-PP
O	1053	1056	the	the	DT	B-NP
O	1057	1065	increase	increase	NN	I-NP
O	1066	1068	in	in	IN	B-PP
O	1069	1071	Mr	Mr	NN	B-NP
O	1072	1074	72	72	CD	I-NP
O	1074	1075	,	,	,	I-NP
O	1075	1078	000	000	CD	I-NP
O	1079	1083	type	type	NN	I-NP
O	1084	1086	IV	IV	CD	I-NP
O	1087	1098	collagenase	collagenase	NN	I-NP
O	1099	1107	activity	activity	NN	I-NP
O	1108	1111	and	and	CC	I-NP
O	1112	1124	angiogenesis	angiogenesis	NN	I-NP
O	1125	1135	attributed	attribute	VBN	B-VP
O	1136	1138	to	to	TO	B-PP
O	1139	1142	the	the	DT	B-NP
O	1143	1152	induction	induction	NN	I-NP
O	1153	1155	of	of	IN	B-PP
O	1156	1158	IL	IL	NN	B-NP
O	1158	1159	-	-	HYPH	O
O	1159	1160	8	8	CD	B-NP
O	1161	1166	after	after	IN	B-PP
O	1167	1178	irradiation	irradiation	NN	B-NP
O	1178	1179	.	.	.	O

O	1180	1183	The	The	DT	B-NP
O	1184	1195	acquisition	acquisition	NN	I-NP
O	1196	1198	of	of	IN	B-PP
O	1199	1202	the	the	DT	B-NP
O	1203	1213	metastatic	metastatic	JJ	I-NP
O	1214	1223	phenotype	phenotype	NN	I-NP
O	1224	1231	induced	induce	VBN	B-VP
O	1232	1234	by	by	IN	B-PP
O	1235	1237	UV	UV	NN	B-NP
O	1237	1238	-	-	HYPH	B-NP
O	1238	1239	B	B	NN	I-NP
O	1240	1245	could	could	MD	B-VP
O	1246	1249	not	not	RB	I-VP
O	1250	1252	be	be	VB	I-VP
O	1253	1263	attributed	attribute	VBN	I-VP
O	1264	1266	to	to	TO	B-PP
O	1267	1280	abnormalities	abnormality	NNS	B-NP
O	1281	1283	in	in	IN	B-PP
O	1284	1287	the	the	DT	B-NP
O	1288	1291	p53	p53	NN	I-NP
O	1292	1294	or	or	CC	I-NP
O	1295	1298	MTS	MTS	NN	I-NP
O	1298	1299	-	-	HYPH	B-NP
O	1299	1300	1	1	CD	I-NP
O	1301	1302	(	(	(	O
O	1302	1309	p16INK4	p16INK4	NN	B-NP
O	1309	1310	)	)	)	O
O	1311	1316	genes	gene	NNS	B-NP
O	1316	1317	.	.	.	O

O	1318	1320	To	To	TO	B-PP
O	1321	1324	the	the	DT	B-NP
O	1325	1329	best	good	JJS	I-NP
O	1330	1332	of	of	IN	B-PP
O	1333	1336	our	our	PRP$	B-NP
O	1337	1346	knowledge	knowledge	NN	I-NP
O	1346	1347	,	,	,	O
O	1348	1352	this	this	DT	B-NP
O	1353	1355	is	be	VBZ	B-VP
O	1356	1359	the	the	DT	B-NP
O	1360	1365	first	first	JJ	I-NP
O	1366	1372	report	report	NN	I-NP
O	1373	1375	to	to	TO	B-VP
O	1376	1380	show	show	VB	I-VP
O	1381	1385	that	that	IN	B-SBAR
O	1386	1388	UV	UV	NN	B-NP
O	1388	1389	-	-	HYPH	B-NP
O	1389	1390	B	B	NN	I-NP
O	1391	1394	can	can	MD	B-VP
O	1395	1403	increase	increase	VB	I-VP
O	1404	1407	the	the	DT	B-NP
O	1408	1422	aggressiveness	aggressiveness	NN	I-NP
O	1423	1425	of	of	IN	B-PP
O	1426	1431	human	human	JJ	B-NP
B-Cancer	1432	1441	cutaneous	cutaneous	JJ	I-NP
I-Cancer	1442	1450	melanoma	melanoma	NN	I-NP
O	1451	1454	for	for	IN	B-PP
O	1455	1461	growth	growth	NN	B-NP
O	1462	1465	and	and	CC	I-NP
O	1466	1476	metastasis	metastasis	NN	I-NP
O	1476	1477	.	.	.	O

